¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-20
±³À°ÀÏÀÚ : 2020-11-20
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2020 KALC International Conference      
ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
´ã´çÀÚ : ½ÉÇöÁ¤ 
¿¬¶ôó : 02-741-8540  
À̸ÞÀÏ : kalc@lungca.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, °áÇÙ°ú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú      
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í       
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 08:00~08:40 Tumor Infiltrating Lymphocytes and the Microenvironment as Biomarkers for Lung Cancer  David Rimm(Yale University School of Medicine) 
È޽Ġ11¿ù 20ÀÏ  08:40~08:50 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 08:50~09:30 Present and Future Perspectives of First-Line Checkpoint Inhibitor for Stage IV Nonsmall Cell Lung Cancer  David Carbone(The Ohio State University) 
È޽Ġ11¿ù 20ÀÏ  09:30~09:40 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 09:40~10:05 Harms, benefits and cost effectiveness of lc screening  Harry J. de Koning(Erasmus University Medical Center) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 10:05~10:30 LDCT Screening in Non-Smokers in Taiwan  Pan-Chyr Yang(National Taiwan University) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 10:30~10:55 Imaging Biomarkers in Lung Cancer Screening  ±¸Áø¸ð(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 10:55~11:20 Liquid Biomarkers in Lung Cancer Screening  À̰迵(°Ç±¹ÀÇ´ë) 
È޽Ġ11¿ù 20ÀÏ  11:20~11:30 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 11:30~12:20 Is it time for a paradigm shift in first line treatment of advanced NSCLC?  ±èÇý·Ã(¿¬¼¼ÀÇ´ë) 
È޽Ġ11¿ù 20ÀÏ  12:20~12:40 Break&ÃÑȸ  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 12:40~13:05 Predictive Biomarkers for Efficacy of Immune Checkpoint Blockades in Lung Cancer  David Carbone(The Ohio State University) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 13:05~13:30 Translation Research in Immunotherapy for Lung Cancer  Hidetoshi Hayashi(Kindai University) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 13:30~13:55 Is HyperProgression Real, or How Do We Prepare for It?  ¼±Á¾¹«(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 13:55~14:20 If Less Is Good, More Is Better_Combination of ImmunoTx  ÀÌ´ëÈ£(¿ï»êÀÇ´ë) 
È޽Ġ11¿ù 20ÀÏ  14:20~14:30 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 14:30~14:55 Evolution of Acquired Resistance to Targeted Therapies for Lung Cancer  Aaron Hata(Massachusetts General HospitalHarvard Medical School) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 14:55~15:20 Treatment for Advanced ALK, ROS1-Rearranged Lung Cancer  ±èµ¿¿Ï(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 15:20~15:45 Treatment for Advanced MET, RET-Altered Lung Cancer  Yasushi Goto(National Hospital Organization Kyushu Cancer Center) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 15:45~16:10 Treatment for Other Minor Mutations-Positive Advanced Lung Cancer  °­ÀºÁÖ(°í·ÁÀÇ´ë) 
È޽Ġ11¿ù 20ÀÏ  16:10~16:20 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 16:20~16:45 E-Cigarettes and Vaping-Related Lung Injury  Jay H. Ryu(Mayo Clinic College of Medicine and Science) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 16:45~17:10 Current Status of Smoking Cessation with Heated Tobacco Products use in Japan  Takahiro Tabuchi(Osaka international Cancer institute) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 17:10~17:35 Current status of smoking cessation program in Korea and COVID-19 risk in smokers  ÃµÀº¹Ì(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 17:35~18:00 Pharmacotherapy for Smoking Cessation and Nicotine Dependence  ÃÖÇý¼÷(°æÈñÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÇǺΰúÀÇ»çȸ Á¦2ȸ ´ëÀü/¼¼Á¾/Ãæû Çмú ½ÉÆ÷Áö¿ò : 2020-11-21
´ÙÀ½±Û ´ëÇÑÆó¾ÏÇÐȸ (¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-19
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20499 ¼­¿ï Çѱ¹Á¤½ÅÄ¡·áÇÐȸ Á¤½ÅÄ¡·á Áõ·Ê¹ßÇ¥ : 2024-05-11 0 50 2024-04-29
20498 ºÎ»ê ¸¸¼ºÆó¼â °ü»óµ¿¸Æ ÁßÀç½Ã¼ú¿¬±¸È¸ The 23rd K-CTO(Korean Chronic Total Occlusion Club) Live Demonstration : 2024-05-11 0 39 2024-04-29
20497 ¼­¿ï ´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11 0 39 2024-04-29
20496 ¼­¿ï 2024 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-11 0 24 2024-04-29
20495 ¼­¿ï Á¦77Â÷ ´ëÇÑû°¢ÇÐȸ Çмú´ëȸ : 2024-05-11 0 48 2024-04-29
20494 ÀÎõ Á¦9ȸ °¡Ãµ´ë ±æº´¿ø ½Å°æ¿Ü°ú ¾÷µ¥ÀÌÆ® ½ÉÆ÷Áö¿ò (G-NeUS) : 2024-05-11 0 48 2024-04-29
20493 ´ëÀü 2024³â ´ëÇѽŰæÁßÀçÄ¡·áÀÇÇÐȸ Ãá°èÇмú´ëȸ & Basic Training Course : 2024-05-11 0 30 2024-04-29
20492 ±¤ÁÖ 2024³â ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Á¦37Â÷ Çмú´ëȸDAY2 : 2024-05-11 0 38 2024-04-29
20491 ¼­¿ï Á¦50ȸ ´ëÇÑÀÓ»óÇǺÎÄ¡·á¿¬±¸È¸ ±³À°½ÉÆ÷Áö¾ö : 2024-05-11 0 38 2024-04-29
20490 ¼­¿ï ÇѾç´ëÇб³º´¿ø Á¤Çü¿Ü°ú ⸳ 52Áֳ⠱â³äÇмú´ëȸ : 2024-05-11 0 78 2024-04-29
20489 ¼­¿ï °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ¼ºÇü¿Ü°úÇб³½Ç â¸³ 50Áֳ⠱â³ä Çмú´ëȸ : 2024-05-11 0 40 2024-04-29
20488 °æ±â ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2024 Spring Semi-Annual Meeting (2ÀÏÂ÷) : 2024-05-11 0 42 2024-04-29
20487 °­¿ø 2024³â ´ëÇѺ´¸®ÇÐȸ º½Çмú´ëȸ(2ÀÏÂ÷) : 2024-05-10 0 40 2024-04-29
20486 ¼­¿ï 2024 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-10 0 67 2024-04-29
20485 ¼­¿ï ´ëÇѳëÀÎÁ¤½ÅÀÇÇÐȸ 2024 Ãá°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2024-05-10 0 35 2024-04-29
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷